<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02134951</url>
  </required_header>
  <id_info>
    <org_study_id>6925</org_study_id>
    <secondary_id>HHS-N-271-2012-0000-7-I</secondary_id>
    <nct_id>NCT02134951</nct_id>
  </id_info>
  <brief_title>Biomarker Assessment of Glutamatergic Target Engagement</brief_title>
  <official_title>Biomarker Assessment of Glutamatergic Target Engagement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the relative feasibility of 2 potential functional
      measures of target engagement (Glx MRS, BOLD fMRI) to systematically assess mGluR 2/3 in drug
      development for psychotic spectrum disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot study of healthy subject to assess the feasibility of Glx MRS and BOLD fMRI
      to measure ketamine induced changes in glutamatergic indices. The investigators will
      randomize 18 subjects at each site. Subjects will be randomized to ketamine or placebo in a
      2:1 ratio and receive two drug challenges separated by at least two weeks. Ketamine challenge
      is used to induce a &quot;glutamate surge&quot; within prefrontal brain regions that can be detected
      using neurochemical and functional imaging techniques. Each subject will receive MRS and BOLD
      fMRI during each challenge day. The goal of the pilot study is to assess the feasibility of
      both the proposed ketamine challenge paradigm and of the proposed imaging-based biomarkers.
      Specific indices to be used in assessing feasibility will include effect size, cross-site and
      cross-subject reliability, safety, and subject tolerability as similar studies will be
      performed independently at Yale and UC Davis. Second this information will be used to select
      and refine final study parameters for a subsequent full proof-of-clinical mechanism (POCM)
      study investigating the effect of Pomaglumetad on ketamine-induced MRS and fMRI effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glutamate + Glutamine (Glx) Response</measure>
    <time_frame>Day 1</time_frame>
    <description>Compare changes in Glx response to infusion of ketamine vs placebo, as measured by proton magnetic resonance spectroscopy (Â¹H MRS). Calculated by post-pre changes in the Glx over creatinine ratios, with higher values indicating higher Glx/creatinine ratios.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Pharmacological Blood-oxygen-level Dependent (pharmacoBOLD) Response</measure>
    <time_frame>Day 14</time_frame>
    <description>Compare changes inpharmacoBOLD in response to infusion of ketamine vs. placebo, as measured by resting state functional magnetic resonance imaging. Calculated by post-pre changes, with higher values indicating higher response</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Healthy Controls</condition>
  <arm_group>
    <arm_group_label>ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV infusion of ketamine 0.23mg/kg bolus over 1 minutes followed by 0.58 mg/kg/hr over 30 minutes then 0.29mg/kg/hr over 64 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group will receive normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>intravenous infusion of saline solution with ketamine</description>
    <arm_group_label>ketamine</arm_group_label>
    <other_name>ketamine hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Normal saline will be used for placebo in this group</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-55

          -  Negative Urine Toxicology

          -  No present or past psychiatric conditions (including substance abuse or dependence,
             with the exception of nicotine dependence)

          -  No family history of schizophrenia in a first-degree relative

        Exclusion Criteria:

          -  Any current DSM IV Axis I disorder and/or past substance abuse of dependence (nicotine
             dependence is allowed)

          -  Any current use of amphetamines, opiates, cocaine, sedative-hypnotics, or cannabis

          -  Current (i.e., within the last 3 months) treatment with any psychotropic medications

          -  Pregnancy, lactation, or lack of use of effective birth control

          -  Presence of positive history of significant medical or neurological illness (including
             any history of seizure), including high blood pressure (SBP &gt;140, DBP &gt;90), low blood
             pressure (SBP &lt;100, DBP &lt;60), orthostatic BP change&gt;20% (1/3 SBP + 2/3 DBP) or cardiac
             illness or resting heart rate &gt;100 or &lt;50

          -  History of significant violent behavior

          -  History of recreational ketamine use, recreational PCP use, or an adverse reaction to
             ketamine. Subjects who have participated prior research ketamine studies will be
             eligible providing they have participated in no more than 5 previous research ketamine
             infusions. Subjects can have infusions not more frequently than biweekly and not more
             than 1/month on average, therefore subjects entering the study will need to wait 1
             month if they had a single infusion and 6 weeks if they have had two closely spaced
             infusions.

          -  Contraindication to MRI scanning, including metal implants or claustrophobia. Metal
             implants, pacemaker, other metal (e.g. shrapnel or surgical prostheses) or
             paramagnetic objects contained within the body which may present a risk to the subject
             or interfere with the MR scan, as determined in consultation with a neuroradiologist
             and according to the guidelines set forth in the following reference book commonly
             used by neuroradiologists: &quot;Guide to MR procedures and metallic objects&quot;, F.G.
             Shellock, Lippincott Williams and Wilkins NY 2001

          -  Color Blindness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey A Lieberman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2014</study_first_submitted>
  <study_first_submitted_qc>May 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2014</study_first_posted>
  <results_first_submitted>June 8, 2017</results_first_submitted>
  <results_first_submitted_qc>February 12, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 13, 2018</results_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>65 subjects were randomized, with results (Number started) reported for the 59 subjects randomized subjects with at least one valid scan</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ketamine</title>
          <description>IV infusion of ketamine 0.23mg/kg bolus over 1 minutes followed by 0.58 mg/kg/hr over 30 minutes then 0.29mg/kg/hr over 64 minutes
Ketamine: intravenous infusion of saline solution with ketamine</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo group will receive normal saline
Normal saline: Normal saline will be used for placebo in this group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39">number of subjects with at least one valid scan</participants>
                <participants group_id="P2" count="20">number of subjects with at least one valid scan</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketamine</title>
          <description>randomized to ketamine</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>randomized to placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.1" spread="9.6"/>
                    <measurement group_id="B2" value="32.2" spread="10.2"/>
                    <measurement group_id="B3" value="31.5" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Glutamate + Glutamine (Glx) Response</title>
        <description>Compare changes in Glx response to infusion of ketamine vs placebo, as measured by proton magnetic resonance spectroscopy (Â¹H MRS). Calculated by post-pre changes in the Glx over creatinine ratios, with higher values indicating higher Glx/creatinine ratios.</description>
        <time_frame>Day 1</time_frame>
        <population>Glx response in 1st 15 minutes post ketamine</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>IV infusion of ketamine 0.23mg/kg bolus over 1 minutes followed by 0.58 mg/kg/hr over 30 minutes then 0.29mg/kg/hr over 64 minutes
Ketamine: intravenous infusion of saline solution with ketamine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo group will receive normal saline
Normal saline: Normal saline will be used for placebo in this group</description>
          </group>
        </group_list>
        <measure>
          <title>Glutamate + Glutamine (Glx) Response</title>
          <description>Compare changes in Glx response to infusion of ketamine vs placebo, as measured by proton magnetic resonance spectroscopy (Â¹H MRS). Calculated by post-pre changes in the Glx over creatinine ratios, with higher values indicating higher Glx/creatinine ratios.</description>
          <population>Glx response in 1st 15 minutes post ketamine</population>
          <units>Glx over creatinine ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.015" spread=".002"/>
                    <measurement group_id="O2" value="0.007" spread=".003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pharmacological Blood-oxygen-level Dependent (pharmacoBOLD) Response</title>
        <description>Compare changes inpharmacoBOLD in response to infusion of ketamine vs. placebo, as measured by resting state functional magnetic resonance imaging. Calculated by post-pre changes, with higher values indicating higher response</description>
        <time_frame>Day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>IV infusion of ketamine 0.23mg/kg bolus over 1 minutes followed by 0.58 mg/kg/hr over 30 minutes then 0.29mg/kg/hr over 64 minutes
Ketamine: intravenous infusion of saline solution with ketamine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo group will receive normal saline
Normal saline: Normal saline will be used for placebo in this group</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacological Blood-oxygen-level Dependent (pharmacoBOLD) Response</title>
          <description>Compare changes inpharmacoBOLD in response to infusion of ketamine vs. placebo, as measured by resting state functional magnetic resonance imaging. Calculated by post-pre changes, with higher values indicating higher response</description>
          <units>BOLD signal units</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".91" spread=".1"/>
                    <measurement group_id="O2" value="-0.27" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ketamine</title>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ketamine psychological effect</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marlene Carlson</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>646-774-8436</phone>
      <email>mc157@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

